01—Abstract
Summary
Summary of the 8-K filed October 16, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) issued a statement on October 16, 2023, to reaffirm its previously provided revenue guidance for its COVID-19 vaccine for the full year 2023, which ranges from $6 billion to $8 billiona.
The company acknowledges the inherent uncertainty in projecting U.S. vaccination rates and stated that performance would fall in the lower half of the range if approximately 50 million doses are administered, and the upper half if approximately 100 million doses are administered. Moderna indicated that it is too early to definitively forecast the market size and expects to have better visibility into U.S. vaccination trends after observing data through October 2023.
Investors can expect a further update on this matter during Moderna's earnings call scheduled for November 2, 2023. The company reiterated its forward-looking statements and cautioned that actual results could differ due to various risks and uncertainties.
02—Key points
Key Highlights
- Moderna reaffirms 2023 COVID-19 vaccine revenue guidance of $6 billion to $8 billion.
- Revenue outlook is sensitive to U.S. vaccination rates, with specific dose administration targets linked to the lower or upper half of the guidance range.
- Company believes it is too early to finalize U.S. market size projections for COVID-19 vaccines.
- Improved visibility into U.S. market size is anticipated after October 2023 vaccination trends are observed.
- A further update on COVID-19 vaccine revenue expectations will be provided on the November 2, 2023 earnings call.
- The company is relying on its previously stated guidance from the Q2 earnings release.
- Standard forward-looking statement disclaimer regarding risks and uncertainties is included.
03—Questions
Frequently Asked Questions
Has Moderna changed its full-year 2023 COVID-19 vaccine revenue guidance?
No, Moderna has reaffirmed its previously provided guidance for full-year 2023 COVID-19 vaccine revenues, which remains in the wide range of $6 billion to $8 billion.
What factors are influencing Moderna's COVID-19 vaccine revenue forecast?
The primary factor influencing the forecast is the uncertainty surrounding U.S. vaccination rates. Moderna has indicated that if the U.S. market is around 50 million doses, they expect to be in the lower half of their guidance range, and if the market reaches approximately 100 million doses, they expect to be in the top half.
When will investors receive more clarity on Moderna's COVID-19 vaccine revenue expectations?
Moderna anticipates having improved visibility into the U.S. market size after observing full vaccination trends through October 2023. A further update will be provided during the company's earnings call on November 2, 2023.
04—Continue